Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31080015 | 0.82 | USP2 (0.50) | USP2SMN1; SMN2ESR2NR1H2KDM4E | |
| SCHEMBL120243 | 0.82 | USP2 (0.50) | USP2SMN1; SMN2ESR2NR1H2KDM4E | |
| SCHEMBL29136746 | 0.81 | USP2 (0.43) | USP2SMN1; SMN2ESR2NR1H2KDM4E | |
| SCHEMBL3429052 | 0.81 | MAPK1 (0.51) | ESR2NR1H2MAPK1HDAC1DDB1 | |
| SCHEMBL1968373 | 0.80 | USP2 (0.46) | USP2SMN1; SMN2ESR2NR1H2KDM4E | |
| SCHEMBL31218507 | 0.79 | CHRM2 (0.44) | USP2SMN1; SMN2ESR2NR1H2KDM4E | |
| SCHEMBL2292608 | 0.79 | USP2 (0.52) | USP2SMN1; SMN2ESR2NR1H2MAPK1 | |
| SCHEMBL995131 | 0.78 | USP2 (0.52) | USP2SMN1; SMN2ESR2NR1H2KDM4E | |
| SCHEMBL25422301 | 0.78 | USP2 (0.47) | USP2SMN1; SMN2ESR2NR1H2KDM4E | |
| SCHEMBL13801225 | 0.78 | USP2 (0.50) | USP2SMN1; SMN2ESR2NR1H2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-20160346292-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160346292-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-05-21 | — | — | US | disclosed |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-05-21 | — | — | US | disclosed |
| EP-2637665-B1 | DEXAMETHASONE COMBINATION THERAPY | UNIV TEXAS (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2459535-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346292-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | USP2 1749/4885SMN1; SMN2 4380/4885ESR2 920/4885 |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | USP2 4546/4885SMN1; SMN2 3256/4885ESR2 4773/4885 |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | TYMP, TPMT, TYMS | USP2 2888/4885SMN1; SMN2 87/4885ESR2 4004/4885 |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | USP2 2043/4885SMN1; SMN2 4075/4885ESR2 3133/4885 |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | USP2 1749/4885SMN1; SMN2 4380/4885ESR2 920/4885 |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | HSP90AB1, HSP90B1, HSP90AA1 | USP2 1190/4885SMN1; SMN2 3559/4885ESR2 1578/4885 |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | GSK3B, GSK3A, PYGB | USP2 4385/4885SMN1; SMN2 4203/4885ESR2 2677/4885 |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | TK1, TK2, SLC1A5 | USP2 2756/4885SMN1; SMN2 940/4885ESR2 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.